Arcellx develops novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
04/13/2021 | Series C | $120MM | $xx.xx | $377.76MM | Samsara BioCapital, CAM Capital, Adage, Asymmetry, CaaS Capital, Cambrian Bio, Sixty Degree, Soleus Capital, Surveyor Capital, Suvretta, Terra Magnum Capital Partners, New Enterprise Associates, Novo Holdings, SR One, Takeda Ventures, LG Tech, Clough Capital | |
Price per Share
$xx.xx
Shares Outstanding
57,224,618
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Samsara BioCapital, CAM Capital, Adage, Asymmetry, CaaS Capital, Cambrian Bio, Sixty Degree, Soleus Capital, Surveyor Capital, Suvretta, Terra Magnum Capital Partners, New Enterprise Associates, Novo Holdings, SR One, Takeda Ventures, LG Tech, Clough Capital
|
||||||
10/03/2019 | Series B-2 | $42.84MM | $xx.xx | $181.78MM | Aju IB, Quan Capital, Mirae Asset Venture Investment, Mirae Asset Capital, LG Tech, JVC Investment Partners, Clough Capital, Novo Holdings, S.R. One, New Enterprise Associates, Takeda Ventures | |
Price per Share
$xx.xx
Shares Outstanding
21,958,284
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Aju IB, Quan Capital, Mirae Asset Venture Investment, Mirae Asset Capital, LG Tech, JVC Investment Partners, Clough Capital, Novo Holdings, S.R. One, New Enterprise Associates, Takeda Ventures
|
||||||
10/03/2019 | Series B-1 | $42.84MM | $xx.xx | $181.78MM | Aju IB, Quan Capital, Mirae Asset Venture Investment, Mirae Asset Capital, LG Tech, JVC Investment Partners, Clough Capital, Novo Holdings, S.R. One, New Enterprise Associates, Takeda Ventures | |
Price per Share
$xx.xx
Shares Outstanding
27,444,339
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Aju IB, Quan Capital, Mirae Asset Venture Investment, Mirae Asset Capital, LG Tech, JVC Investment Partners, Clough Capital, Novo Holdings, S.R. One, New Enterprise Associates, Takeda Ventures
|
||||||
09/01/2017 | Series A | $29.8MM | $xx.xx | $37.24MM | Novo Ventures | |
Price per Share
$xx.xx
Shares Outstanding
29,795,227
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Novo Ventures
|